TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02154893

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound plus Laser and therapeutic exercise
Description: Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound plus Laser
Description: Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
Study: NCT00774735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 30 mg given in combination with lopinavir/ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1349572
Description: 30 mg in combination with darunavir/ritonavir
Study: NCT05330663

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low protein diet with Fresubin® renal
Description: Low protein diet with Fresubin® renal Dosage: 1 bottle per day as a replacement for one regular meal. All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight.

Intervention type: OTHER
Group type: OTHER
Intervention: Low protein diet with normal food
Description: All patients will get individualized dietary counseling aimed at achieving a protein intake of 0.6-0.8 g/kg actual body weight/day and an energy intake of 30-35 kcal/kg actual body weight/day.
Study: NCT01335711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChronVac-C + SOC
Description: IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ChronVac-C + SOC
Description: IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.~SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SOC
Description: SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)
Study: NCT00262834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally, conventional surgery to follow.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Undergo conventional surgery
Study: NCT01772992

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CVCTPLUS
Description: For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
Study: NCT00003457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
Study: NCT01492881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Oral, 400mg, taken days 4 through 11 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Intravenous, 30mg/m2, Day 4
Study: NCT04108546

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture device
Description: The technical characteristics of the device will be: power supply with alkaline batteries (4 pieces), 6V voltage, 6 independently regulated channels, symmetrical biphasic rectangular pulse, excitation from pen type electrode 0.48mA, with high 0.32mA + / -25% \& low 0.16mA +/- 25%. Three preset programs to avoid tolerance effect: program 1) 1-6Hz, program 2) 30-100Hz, program 3) 2-100Hz. Low frequencies (2Hz) cause release of endorphins in the brain and enkephalins in the spinal cord, high frequencies (30-100Hz) cause release of dynorphins in the spinal cord, while medium frequencies (15Hz) cause simultaneous release of endorphin and dynorphin. At low frequencies slow diffuse analgesia is achieved with a long duration of analgesic effect, while at high frequencies rapid local analgesic effect of short duration is achieved.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: Ropivacaine (Naropeine) 0.2%, 5-7% ml, and Fentanyl 25mcg
Study: NCT00709163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nesiritide
Description: The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Dextrose
Description: The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
Study: NCT03399110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: oxaliplatin 130 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000mg/m2
Study: NCT01407185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistive Exercise Training
Description: Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
Study: NCT01245595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: 5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT01151670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: Pioglitazone 22.5 mg daily before, during and after radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
Study: NCT02464059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
Study: NCT03454100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: multisectoral package of activities
Description: A multi-sectoral package of village level activities, including having a well dug, a shared latrine installed, training on handwashing and hygiene across the water chain, training on conservation agriculture techniques, care groups for pregnant and breastfeeding mothers, and training on market gardens.
Study: NCT01637012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation
Description: index angioplasty with ALEX stent implatation
Study: NCT00086346

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus (Rapamune)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine or Tacrolimus
Study: NCT02416791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Therapy
Description: Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic Therapy
Description: Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
Study: NCT02154893

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Utrasound plus Laser Placebo
Description: The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
Study: NCT00919061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 800 mg/m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 20 mg /m\^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg PO once a day continuously.
Study: NCT01655433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Velomedix APLS device
Description: Velomedix, Automated Peritoneal Lavage System

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Hypothermia Treatment
Study: NCT01190826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024
Description: Target dose of 10 mg ASM-024 administered once by inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASM-024 100 mg
Description: Target dose of 100 mg ASM-024 administered once by inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered once by inhalation
Study: NCT03354156

Intervention type: DRUG
Intervention: statin treatment
Description: The patients with elevated LDL receive statin treatment in the context of normal patient care (so this is NOT an intervention of the study)
Study: NCT04346290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Initial infusion dose of dexmedetomidine is 0.4 mcg/kg/min, maintenance infusion dose is 0.1-0.7 mcg/kg/min
Study: NCT03690986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VX15/2503
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02416791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.
Study: NCT03690986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03242993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]-AzaFol
Description: \[18F\]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folarell
Description: For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to \[18F\]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.~Folarell® is a folic acid preparation for intravenous or intramuscular injection
Study: NCT00115258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: parenteral nutrition titrated to measured REE
Study: NCT03765944

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: SIngle administration under fasted condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sirolimus
Description: SIngle administration under fasted condition
Study: NCT00149552

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: zinc
Description: supplementation with zinc gluconate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc
Description: supplementation with zinc gluconate
Study: NCT02343562

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotics
Description: Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Multivitamin off-the-counter.
Study: NCT04890704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Curcuminoid
Description: Patients were stratified according to baseline eGFR and diabetes status with 1:1 assignment into curcuminoids and placebo group. Curcuminoids (250 mg capsules) were purchased from the Government Pharmaceutical Organization of Thailand (Anti-ox® registration number 1A 1/60(H)), which contained curcumin: demethoxycurcumin: bis-demothoxycurcumin at the ratio of 1:0.5:0.2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical capsules were used for the placebo from the same manufacturer.
Study: NCT00084617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given orally
Study: NCT02720224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: 15 mg \[14C\]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
Study: NCT02556099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: drug to be administered
Study: NCT03178422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CQSS2
Description: Nicotine Replacement Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NicoDerm CQ Patch
Description: Nicotine Replacement Therapy
Study: NCT01230385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lersivirine
Description: Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lersivirine
Description: Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
Study: NCT01770782

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgically Assisted Rapid Maxillary Expansion (SARME)
Description: Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
Study: NCT02395250

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-GPC3 CAR T
Study: NCT03432637

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spontaneous ventilation
Description: thoracoscopic lobectomy under spontaneous ventilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intubated anesthesia with single-lung mechanical ventilation
Description: undergoing thoracoscopic lobectomy under intubated anesthesia with single-lung mechanical ventilation
Study: NCT00496717

Intervention type: DEVICE
Intervention: Helicoidal fast scann
Description: Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
Study: NCT00502242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramipril
Description: Capsule - initial treatment is 5 mg (active)- oral - once per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ramipril
Description: Capsule - initial treatment is 5 mg (placebo) - oral - once per day
Study: NCT03817853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab 1000 mg IV infusion, administered on Day 1, 8 and 15 during Cycle 1, and on Day 1 of subsequent cycles, for 6-8 cycles. Each cycle is 21 or 28 days long depending on the chemotherapy regimen allocated. Maintenance obinutuzumab monotherapy in patients who achieve at least a partial response, after induction therapy will be administered a dose of 1000 mg once every 8 weeks for 2 years or until disease progression (whichever occurs first).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered on Days 1 and 2 for Cycles 1-6 at a dose of 90 mg/m2/day, for six 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle, for six cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone/Prednisolone/Methylprednisolone
Description: Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle, for six cycles for CHOP treatment or eight cycles for CVP treatment.
Study: NCT05310682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data informed Platfrom for health
Description: The DIPH promotes local data use for decision-making, priority-setting, planning and course correction at the district level by introducing a structured and collaborative process within the administration cadre. The DIPH is delivered as a package of job aids and guidelines. It involves grouping stakeholders who are brought together to deliberate on issues in a virtual platform facilitated by regular meetings. The package facilitates stakeholders' meetings in five steps: Assessment, Engagement, Definition, Planning and Follow-up. Together, these steps make up one whole cycle of the DIPH completed over four months. Each cycle looks at a specific health theme, identified in the early stages of the cycle itself. The package also includes a digital interface where everyone can regularly review data and check on progress. Note: LSHTM has exempted this study from having a sponsor, as DIPH is implemented at the health system administration level.
Study: NCT02685176

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)
Description: A heater (STK Heatpac) will be used in the active warming arms of the study.
Study: NCT01770782

Intervention type: OTHER
Group type: OTHER
Intervention: Laser Scanner
Description: Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
Study: NCT02151396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory training

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional magnetic resonance imaging (fMRI)
Study: NCT01278199

Intervention type: OTHER
Group type: OTHER
Intervention: Medicals measures
Description: Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 \> 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.~If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.~The administration of antibiotherapy by general mode according to the clinician appreciation.~The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bronchial artery embolization
Description: The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
Study: NCT02178449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT02416791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham tDCS
Description: In sham tDCS, no current will be delivered through the tDCS device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Physical therapy will be administered for 40 minutes.
Study: NCT02766400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Training
Study: NCT02416791

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy will be administered for 40 minutes.
Study: NCT02766400

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Directed Training